VitsGen Therapeutics Receives FDA Orphan Drug Designation for FAP-Targeted Radiopharmaceutical 177Lu-FAP-VG11
VitsGen’s IND Application for 177Lu-FAP-VG11 Injection for Advanced Malignant Solid Tumors Accepted by China’s NMPA CDE
Advancing the Frontier | Investigator-Initiated Trial of 177Lu-FAP-VG11 Injection in Advanced Solid Tumors Officially Launched
Dr. Keene Wei, Founder of Vitsgen, Invited to Speak at the 3rd Global Nuclear Medicine Development Summit 2026, Sharing Cutting-Edge Insights on Radiopharmaceutical Conjugate Design
Dr. Keene Wei, Founder of VitsGen, to Present Frontier Insights on Intelligent Design of Radiopharmaceuticals at the 2nd TRP Targeted Radiopharmaceutical Summit
